Advertisement

U.S. markets closed

S&P Futures
5,763.50
+1.50(+0.03%)
Dow Futures
42,434.00
-9.00(-0.02%)
Nasdaq Futures
20,041.00
+12.75(+0.06%)
Russell 2000 Futures
2,259.30
+6.70(+0.30%)
Crude Oil
71.03
+0.03(+0.04%)
Gold
2,645.40
-0.80(-0.03%)

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

3.2800

-0.1100

(-3.24%)

At close: 04:00PM EDT

3.3700

+0.09

(+2.74%)

After hours:

06:58PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohortCompany expects to have mature median rPFS no later than early 2025MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8
Zacks
Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't?
Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.
GlobeNewswire
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m. ETROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prosta